HempNewsBreaks – EVIO, Inc. (EVIO) Signs Non-Binding LOI to Acquire Licensed Cannabis Laboratory in Berkeley, CA

EVIO (OTCQB: EVIO) this morning announced that it has signed a non-binding Letter of Intent (“LOI”) to acquire 60% of C3 Labs, LLC. C3 Labs is located in Berkeley, CA, which accelerates the company’s intent to expand into Northern California prior to the anticipated increase in demand for analytical testing services. Subject to customary closing conditions, the transaction is expected to close in the first quarter of 2018. “C3 Labs been serving the cannabis industry for years, providing product formulation, research and development services that aligns with EVIO’s longer term strategy to expand our scope of services. We are working to close this transaction in an expeditious manner to begin serving the California market by first quarter 2018,” EVIO CEO William Waldrop stated in the news release.

To view the full press release, visit http://cnw.fm/7KtaP

About EVIO, Inc.

EVIO, Inc. is an Oregon-based life sciences company that provides analytical testing services, management advisory services and scientific research to the legal cannabis and hemp industries. The company’s EVIO Labs division operates state-of-the-art facilities and offers accredited testing methodologies to ensure the safety and quality of the nation’s cannabis supply. For more information, visit the company’s website at www.EvioLabs.com.

More from CannabisNewsBreaks

About HempWire

HempWire (HW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) HempNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.

For more information please visit https://www.hempwire.com

Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/

HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net

Chris@HW

Share
Published by
Chris@HW

Recent Posts

HempNewsBreaks – Turning Point Brands Inc. (NYSE: TPB) Closes $300M Senior Secured Notes Offering 

Turning Point Brands (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products, recently…

2 months ago

HempNewsBreaks – WEED Inc. (BUDZ) Announces 2024 Highlights, Plans to Expand into Consumer Packaged Goods

WEED Inc. (OTCQB: BUDZ), a global cannabis and hemp bioresearch company based in the U.S.,…

4 months ago

HempNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Closes $3.6M Registered Direct

Flora (NASDAQ: FLGC) has closed a registered direct offering to institutional investors for the aggregate…

4 months ago

HempNewsBreaks – Golden Triangle Ventures Inc. (GTVH) to Host Spaces Event, Share Comprehensive Update on Destino Ranch

Golden Triangle Ventures (OTC: GTVH) (“GTV”) today announced its plans to host a Spaces call…

5 months ago

HempNewsBreaks – CBD Life Sciences Inc. (CBDL) Poised to Become Game Changer in the Hemp Industry

CBD Life Sciences (OTC: CBDL) today announced its potential for explosive profits in a $70…

6 months ago

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Friday that…

7 months ago